Preclinical and clinical studies with combinations of pemetrexed and gemcitabine

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

The novel antimetabolite pemetrexed inhibits the folate-dependent enzymes thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This agent is broadly active in a wide variety of solid tumors, including non-small cell lung, breast, bladder, head and neck, and ovarian cancers, as well as mesothelioma. Gemcitabine is a pyrimidine nucleoside antimetabolite that is approved worldwide for the treatment of pancreatic and non-small cell lung cancers, and bladder cancer outside the United States. In addition, gemcitabine is active against a broad range of tumors including breast, ovarian, and other cancers. Preclinical studies have shown cytotoxic synergy when pemetrexed is combined with gemcitabine. Based on these data, a phase I study of this combination was performed that showed striking activity. Phase II studies of this combination are being performed in breast and non-small cell lung cancer. In addition, a phase III study in pancreatic cancer is ongoing.

Original languageEnglish (US)
Pages (from-to)30-34
Number of pages5
JournalSeminars in Oncology
Volume29
Issue number6 SUPPL. 18
StatePublished - Jan 1 2002

Fingerprint

gemcitabine
Pemetrexed
Antimetabolites
Urinary Bladder Neoplasms
Non-Small Cell Lung Carcinoma
Ovarian Neoplasms
Breast
Hydroxymethyl and Formyl Transferases
Pyrimidine Nucleosides
Mesothelioma
Head and Neck Neoplasms
Pancreatic Neoplasms
Folic Acid
Urinary Bladder
Breast Neoplasms
Lung
Enzymes
Clinical Studies
Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Preclinical and clinical studies with combinations of pemetrexed and gemcitabine. / Adjei, Alex.

In: Seminars in Oncology, Vol. 29, No. 6 SUPPL. 18, 01.01.2002, p. 30-34.

Research output: Contribution to journalReview article

@article{b0687afc69694d2296cd071b08c78e60,
title = "Preclinical and clinical studies with combinations of pemetrexed and gemcitabine",
abstract = "The novel antimetabolite pemetrexed inhibits the folate-dependent enzymes thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This agent is broadly active in a wide variety of solid tumors, including non-small cell lung, breast, bladder, head and neck, and ovarian cancers, as well as mesothelioma. Gemcitabine is a pyrimidine nucleoside antimetabolite that is approved worldwide for the treatment of pancreatic and non-small cell lung cancers, and bladder cancer outside the United States. In addition, gemcitabine is active against a broad range of tumors including breast, ovarian, and other cancers. Preclinical studies have shown cytotoxic synergy when pemetrexed is combined with gemcitabine. Based on these data, a phase I study of this combination was performed that showed striking activity. Phase II studies of this combination are being performed in breast and non-small cell lung cancer. In addition, a phase III study in pancreatic cancer is ongoing.",
author = "Alex Adjei",
year = "2002",
month = "1",
day = "1",
language = "English (US)",
volume = "29",
pages = "30--34",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "6 SUPPL. 18",

}

TY - JOUR

T1 - Preclinical and clinical studies with combinations of pemetrexed and gemcitabine

AU - Adjei, Alex

PY - 2002/1/1

Y1 - 2002/1/1

N2 - The novel antimetabolite pemetrexed inhibits the folate-dependent enzymes thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This agent is broadly active in a wide variety of solid tumors, including non-small cell lung, breast, bladder, head and neck, and ovarian cancers, as well as mesothelioma. Gemcitabine is a pyrimidine nucleoside antimetabolite that is approved worldwide for the treatment of pancreatic and non-small cell lung cancers, and bladder cancer outside the United States. In addition, gemcitabine is active against a broad range of tumors including breast, ovarian, and other cancers. Preclinical studies have shown cytotoxic synergy when pemetrexed is combined with gemcitabine. Based on these data, a phase I study of this combination was performed that showed striking activity. Phase II studies of this combination are being performed in breast and non-small cell lung cancer. In addition, a phase III study in pancreatic cancer is ongoing.

AB - The novel antimetabolite pemetrexed inhibits the folate-dependent enzymes thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This agent is broadly active in a wide variety of solid tumors, including non-small cell lung, breast, bladder, head and neck, and ovarian cancers, as well as mesothelioma. Gemcitabine is a pyrimidine nucleoside antimetabolite that is approved worldwide for the treatment of pancreatic and non-small cell lung cancers, and bladder cancer outside the United States. In addition, gemcitabine is active against a broad range of tumors including breast, ovarian, and other cancers. Preclinical studies have shown cytotoxic synergy when pemetrexed is combined with gemcitabine. Based on these data, a phase I study of this combination was performed that showed striking activity. Phase II studies of this combination are being performed in breast and non-small cell lung cancer. In addition, a phase III study in pancreatic cancer is ongoing.

UR - http://www.scopus.com/inward/record.url?scp=0036984020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036984020&partnerID=8YFLogxK

M3 - Review article

C2 - 12571808

AN - SCOPUS:0036984020

VL - 29

SP - 30

EP - 34

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 6 SUPPL. 18

ER -